Syndax Pharmaceuticals (SNDX)
$20.96
+0.16
(+0.77%)▲
Insights on Syndax Pharmaceuticals
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 45.1% return, outperforming this stock by 47.6%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 238.3% return, outperforming this stock by 202.8%
Performance
- $20.75$21.37$20.96
1.0%
Downside
Day's Volatility :2.9%
Upside
1.92%
- $11.22$25.34$20.96
46.47%
Downside
52 Weeks Volatility :55.72%
Upside
17.28%
Returns
| Period | Syndax Pharmaceuticals | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -1.27% | -0.4% | 0.0% |
6 Months | 84.02% | 9.6% | 0.0% |
1 Year | -1.5% | 3.9% | -1.3% |
3 Years | 35.49% | 12.8% | -22.1% |
Highlights
Market Capitalization | 1.7B |
Book Value | $6.53 |
Earnings Per Share (EPS) | -2.98 |
PEG Ratio | 0.0 |
Wall Street Target Price | 35.27 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -25.89% |
Return On Equity TTM | -40.99% |
Revenue TTM | 126.6M |
Revenue Per Share TTM | 2.17 |
Quarterly Revenue Growth YOY | 33297.4% |
Gross Profit TTM | 139.7M |
EBITDA | -229.9M |
Diluted Eps TTM | -2.98 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.86 |
EPS Estimate Next Year | -2.9 |
EPS Estimate Current Quarter | -0.99 |
EPS Estimate Next Quarter | -0.85 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 68.27%
Technicals Summary
Sell
Neutral
Buy
Syndax Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Syndax Pharmaceuticals | -6.6% | 84.02% | -1.5% | 35.49% | 201.15% |
 Moderna, Inc. | -5.36% | 32.83% | -24.38% | -39.84% | 322.91% |
 Regeneron Pharmaceuticals, Inc. | -6.34% | 13.15% | 12.94% | 84.22% | 161.57% |
 Novo Nordisk A/s | -2.94% | 28.97% | 46.95% | 238.27% | 414.84% |
 Vertex Pharmaceuticals Incorporated | -3.87% | 8.77% | 20.15% | 83.53% | 128.04% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Syndax Pharmaceuticals | 0.0 | NA | 0.0 | -3.86 | -0.41 | -0.26 | NA | 6.53 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.77 | 25.77 | 1.46 | 45.22 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.13 | 46.13 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.39 | 28.39 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Syndax Pharmaceuticals | Buy | $1.7B | 201.15% | 0.0 | 0.0% |
Moderna, Inc. | Buy | $38.8B | 322.91% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.4B | 161.57% | 25.77 | 30.14% |
Novo Nordisk A/s | Buy | $551.3B | 414.84% | 46.13 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 128.04% | 28.39 | 36.68% |
Institutional Holdings
Wellington Management Company LLP
8.93%BlackRock Inc
8.26%Kynam Capital Management, LP
6.66%State Street Corporation
5.90%Vanguard Group Inc
5.10%venBio Select Advisor LLC
4.97%
Company Information
syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.
Organization | Syndax Pharmaceuticals |
Employees | 184 |
CEO | Mr. Michael A. Metzger M.B.A. |
Industry | Health Technology |
